Transfusion-Related Acute Lung Injury (TRALI) After Convalescent Plasma Therapy in COVID-19 Patient
Yıl: 2021 Cilt: 12 Sayı: 2 Sayfa Aralığı: 60 - 63 Metin Dili: İngilizce DOI: 10.37678/dcybd.2021.2683 İndeks Tarihi: 15-02-2022
Transfusion-Related Acute Lung Injury (TRALI) After Convalescent Plasma Therapy in COVID-19 Patient
Öz: The coronavirus disease 2019 (COVID-19) continues to spread all around the world. Mortality and morbidity rates are increasing-up to now. Although convalescent plasma therapy can be thought to be useful in the treatment of COVID-19, it carries potential risks, such as transfusion-related acute lung injury (TRALI). In COVID-19 infection, tachypnea, tachycardia, increased need for oxygenation, and the presence of bilateral widespread infiltrates on radiological imagings are evaluated as acute respiratory distress syndrome (ARDS). This clinical situation may develop independently from disease progression in patients receiving convalescent plasma therapy and it is called TRALI. We aimed to present our case to discuss the difficulty of this situation to differentiate from COVID-19 related ARDS
Anahtar Kelime: Belge Türü: Makale Makale Türü: Diğer Erişim Türü: Erişime Açık
- 1. World Health Organization (2021). Novel Coronavirus (2019- nCoV) situation reports. https://www.who.int/emergencies/ diseases/novel-coronavirus-2019/situation-reports
- 2. Cao Y-C, Deng Q-X, Dai S-X. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: an evaluation of the evidence. Travel Med Infect Dis 2020;35:101647. [CrossRef]
- 3. Cao B, Wang Y, Wen D, et al. A trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020;382:1787– 99. [CrossRef]
- 4. Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and nazithromycin as a treatment of COVID-19: results of an open- label non-randomized clinical trial. Int J Antimicrob Agents 2020;56:105949. [CrossRef]
- 5. Michot J-M, Albiges L, Chaput N, et al. Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report. Ann Oncol 2020;31:961–4. [CrossRef]
- 6. Zhang C, Wu Z, Li J-W, et al. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents 2020;55:105954. [CrossRef]
- 7. Cunningham AC, Goh HP, Koh D. Treatment of COVID-19: old tricks for new challenges. Crit Care 2020;16:24:91. [CrossRef]
- 8. Luke TC, Kilbane EM, Jackson JL, et al. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 2006;145:599–609. [CrossRef]
- 9. Hung IF, To KK, Lee C-K, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011;52:447–56. [CrossRef]
- 10. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al.The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-nalysis. J Infect Dis 2015;211:80–90. [CrossRef]
- 11. Shen C,Wang Z, Zhao F, et al.Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma. JAMA 2020;28:323:1582–9. [CrossRef]
- 12. Zhang B, Liu S, Tan T, et al. Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection. Chest 2020;158:e9–13. [CrossRef]
- 13. Vlaar APJ, Juffermans NP. Transfusion-related acute lung injury: a clinical review. Lancet 2013;382:984–94. [CrossRef]
- 14. Arabi Y, Balkhy H, Hajeer AH, et al. Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. SpringerPlus 2015;19:4:709. [CrossRef]
- 15. Ko J-H, Seok H, Cho SY, et al. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: asingle centre experience. Antivir Ther 2018;23:617–22. [CrossRef]
- 16. Fontaine MJ, Malone J, Mullins FM, et al. Diagnosis of transfusion- related acute lung injury: TRALI or not TRALI? Ann Clin Lab Sci 2006;36:53–8. https://pubmed.ncbi.nlm.nih.gov/16501237/
- 17. Silliman CC, Fung YL, Ball JB, et al. Transfusion related acute lung injury: Current concepts and misconceptions. Blood Rev 2009;23:245–55. [CrossRef]
- 18. Jawa RS, Anillo S, Kulaylat MN. Transfusion-related acute lung injury. J Intensive Care Med 2008;23:109–21. [CrossRef]
- 19. Vlaar APJ, Toy P, Fung M, et al. A consensus redefinition of transfusion-related acute lung injury. Transfusion 2019;59:2465–76. [CrossRef]
- 20. Gajic O, Rana R, Winters JL, et al. Transfusion-related acute lung injury in the critically ill: prospective nested case-control study. Am J Respir Crit Care Med 2007;176:886–91. [CrossRef]
| APA | Mermi̇t B, AŞKAR S (2021). Transfusion-Related Acute Lung Injury (TRALI) After Convalescent Plasma Therapy in COVID-19 Patient. , 60 - 63. 10.37678/dcybd.2021.2683 |
| Chicago | Mermi̇t Buket,AŞKAR Selvi Transfusion-Related Acute Lung Injury (TRALI) After Convalescent Plasma Therapy in COVID-19 Patient. (2021): 60 - 63. 10.37678/dcybd.2021.2683 |
| MLA | Mermi̇t Buket,AŞKAR Selvi Transfusion-Related Acute Lung Injury (TRALI) After Convalescent Plasma Therapy in COVID-19 Patient. , 2021, ss.60 - 63. 10.37678/dcybd.2021.2683 |
| AMA | Mermi̇t B,AŞKAR S Transfusion-Related Acute Lung Injury (TRALI) After Convalescent Plasma Therapy in COVID-19 Patient. . 2021; 60 - 63. 10.37678/dcybd.2021.2683 |
| Vancouver | Mermi̇t B,AŞKAR S Transfusion-Related Acute Lung Injury (TRALI) After Convalescent Plasma Therapy in COVID-19 Patient. . 2021; 60 - 63. 10.37678/dcybd.2021.2683 |
| IEEE | Mermi̇t B,AŞKAR S "Transfusion-Related Acute Lung Injury (TRALI) After Convalescent Plasma Therapy in COVID-19 Patient." , ss.60 - 63, 2021. 10.37678/dcybd.2021.2683 |
| ISNAD | Mermi̇t, Buket - AŞKAR, Selvi. "Transfusion-Related Acute Lung Injury (TRALI) After Convalescent Plasma Therapy in COVID-19 Patient". (2021), 60-63. https://doi.org/10.37678/dcybd.2021.2683 |
| APA | Mermi̇t B, AŞKAR S (2021). Transfusion-Related Acute Lung Injury (TRALI) After Convalescent Plasma Therapy in COVID-19 Patient. Journal of critical and intensive care (Online), 12(2), 60 - 63. 10.37678/dcybd.2021.2683 |
| Chicago | Mermi̇t Buket,AŞKAR Selvi Transfusion-Related Acute Lung Injury (TRALI) After Convalescent Plasma Therapy in COVID-19 Patient. Journal of critical and intensive care (Online) 12, no.2 (2021): 60 - 63. 10.37678/dcybd.2021.2683 |
| MLA | Mermi̇t Buket,AŞKAR Selvi Transfusion-Related Acute Lung Injury (TRALI) After Convalescent Plasma Therapy in COVID-19 Patient. Journal of critical and intensive care (Online), vol.12, no.2, 2021, ss.60 - 63. 10.37678/dcybd.2021.2683 |
| AMA | Mermi̇t B,AŞKAR S Transfusion-Related Acute Lung Injury (TRALI) After Convalescent Plasma Therapy in COVID-19 Patient. Journal of critical and intensive care (Online). 2021; 12(2): 60 - 63. 10.37678/dcybd.2021.2683 |
| Vancouver | Mermi̇t B,AŞKAR S Transfusion-Related Acute Lung Injury (TRALI) After Convalescent Plasma Therapy in COVID-19 Patient. Journal of critical and intensive care (Online). 2021; 12(2): 60 - 63. 10.37678/dcybd.2021.2683 |
| IEEE | Mermi̇t B,AŞKAR S "Transfusion-Related Acute Lung Injury (TRALI) After Convalescent Plasma Therapy in COVID-19 Patient." Journal of critical and intensive care (Online), 12, ss.60 - 63, 2021. 10.37678/dcybd.2021.2683 |
| ISNAD | Mermi̇t, Buket - AŞKAR, Selvi. "Transfusion-Related Acute Lung Injury (TRALI) After Convalescent Plasma Therapy in COVID-19 Patient". Journal of critical and intensive care (Online) 12/2 (2021), 60-63. https://doi.org/10.37678/dcybd.2021.2683 |
